<h2 data-section-id="12jcpr2" data-start="0" data-end="42"><strong>Alcohol-associated Liver Disease Market</strong></h2>
<p data-start="44" data-end="771">The <a href="https://www.delveinsight.com/report-store/alcohol-associated-liver-disease-market"><strong>Alcohol-associated Liver Disease (ALD) market</strong></a> is expected to witness substantial expansion during the forecast period owing to the growing burden of chronic alcohol consumption, metabolic comorbidities, and increasing awareness regarding liver disorders. In 2025, the ALD market size across the 7MM was estimated at nearly USD 145 million, with the US accounting for approximately 59% of the total market share. The market is projected to grow at a strong CAGR of 31.1% during 2026&ndash;2036, driven by emerging disease-modifying therapies and precision medicine approaches. Increasing focus on microbiome-based treatments and novel anti-inflammatory agents is also expected to transform the therapeutic landscape significantly.</p>
<ul data-start="773" data-end="995">
<li data-section-id="1wsvy3l" data-start="773" data-end="821">2025 market size in the 7MM: USD 145 million</li>
<li data-section-id="f5ig6o" data-start="822" data-end="858">Expected CAGR (2026&ndash;2036): 31.1%</li>
<li data-section-id="sxw1vi" data-start="859" data-end="914">US contributed nearly 59% of the total market share</li>
<li data-section-id="19nii57" data-start="915" data-end="995">Larsucosterol is projected to generate the highest revenue by 2036 in the US</li>
</ul>
<h2 data-section-id="1l4hhrl" data-start="997" data-end="1045"><strong>Alcohol-associated Liver Disease Epidemiology</strong></h2>
<p data-start="1047" data-end="1756"><a href="https://www.delveinsight.com/report-store/alcohol-associated-liver-disease-epidemiology-forecast"><strong>Alcohol-associated Liver Disease</strong></a> remains one of the leading causes of liver-related morbidity and mortality globally. In 2025, the total diagnosed prevalent cases of ALD across the 7MM were estimated at nearly 12.1 million. Epidemiological analysis highlights that the US represented around 38% of cases, while EU4 and the UK accounted for 39%, followed by Japan with 23%. Disease burden is particularly high in patients with early-stage alcohol-associated steatosis, whereas comparatively fewer patients progress to steatohepatitis and cirrhosis. The increasing prevalence of <a href="https://www.delveinsight.com/report-store/alcohol-use-disorder-market"><strong>alcohol use disorder (AUD)</strong></a>, <a href="https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market"><strong>obesity</strong></a>, and metabolic dysfunction continues to contribute significantly to the rising ALD patient pool.</p>
<ul data-start="1758" data-end="2006">
<li data-section-id="1ffu81h" data-start="1758" data-end="1818">Total diagnosed prevalent cases in the 7MM: 12.1 million</li>
<li data-section-id="74acx9" data-start="1819" data-end="1862">US accounted for 38% of diagnosed cases</li>
<li data-section-id="jydz9c" data-start="1863" data-end="1897">EU4 and the UK contributed 39%</li>
<li data-section-id="bf3n5y" data-start="1898" data-end="1939">Japan represented nearly 23% of cases</li>
<li data-section-id="1ugyd0r" data-start="1940" data-end="2006">Early-stage steatosis remains the most prevalent disease stage</li>
</ul>
<h2 data-section-id="tx9yl4" data-start="2008" data-end="2052"><strong>Alcohol-associated Liver Disease Pipeline</strong></h2>
<p data-start="2054" data-end="2823">The ALD pipeline is evolving rapidly with several companies focusing on novel mechanisms targeting inflammation, fibrosis, metabolic dysfunction, and liver regeneration. Currently, there are no FDA-approved disease-modifying therapies for ALD, creating substantial opportunities for first-in-class treatments. Emerging therapies are being developed using approaches such as FXR agonism, HSD17B13 inhibition, IL-22 targeting, and GLP-1/glucagon receptor modulation. Companies are increasingly investing in precision medicine and biologic therapies to address severe alcohol-associated hepatitis and cirrhosis. The future pipeline is expected to reshape ALD management by offering targeted therapies capable of improving survival outcomes and slowing disease progression.</p>
<h3 data-start="2825" data-end="2843"><strong data-start="2825" data-end="2843">Emerging Drugs</strong></h3>
<ul data-start="2844" data-end="3138">
<li data-section-id="qfsuvi" data-start="2844" data-end="2911">Larsucosterol - Bausch Health - DNA methyltransferase inhibitor</li>
<li data-section-id="1k28mv9" data-start="2912" data-end="2953">GSK4532990 - GSK - HSD17B13 inhibitor</li>
<li data-section-id="1gsfb4t" data-start="2954" data-end="3020">INT-787 - Alphasigma (Intercept Pharmaceuticals) - FXR agonist</li>
<li data-section-id="k4g9ry" data-start="3021" data-end="3071">F-652 - Evive Biotech - IL-22 targeted therapy</li>
<li data-section-id="156cwhv" data-start="3072" data-end="3138">Pemvidutide - Altimmune - GLP-1/glucagon dual receptor agonist</li>
</ul>
<h3 data-start="3140" data-end="3159"><strong data-start="3140" data-end="3159">Key Unmet Needs</strong></h3>
<ul data-start="3160" data-end="3301" data-is-last-node="" data-is-only-node="">
<li data-section-id="1wp80ka" data-start="3160" data-end="3206">Delayed diagnosis and poor early detection</li>
<li data-section-id="drz7gy" data-start="3207" data-end="3251">Lack of reliable non-invasive biomarkers</li>
<li data-section-id="1hy5geb" data-start="3252" data-end="3301" data-is-last-node="">Absence of approved disease-modifying therapies</li>
</ul>

Alcohol-associated Liver Disease (ALD) Market

Alcohol-associated Liver Disease (ALD) Market Infographic

Alcohol-associated Liver Disease (ALD) Market Thumbnail

Alcohol-associated Liver Disease Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape